Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99949
Title:
Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.
Authors:
Von Rohr, A; Ghosh, Anna K; Thatcher, Nick; Stern, Peter L
Abstract:
Treatment with combined IL-2 and alpha-IFN has resulted in synergistic antitumour efficacy in animal studies. The mechanisms responsible for this synergy remain unclear. In this study, several immune parameters which might be involved in mediating antitumour activity have been monitored serially in 15 patients with advanced malignant melanoma or renal cell cancer during treatment with concurrent IL-2 and alpha-IFN. Both drugs were given subcutaneously in low to moderate (outpatient) dosages but for a prolonged duration. This treatment resulted in remarkable immunomodulation. In vivo induction of cytotoxicity against K562 and Daudi target cells was consistently seen, and percentages of peripheral blood cells expressing CD 25 (IL-2 receptor) and CD 56 (Leu-19) increased. In vitro proliferation of lymphocytes in response to IL-2 was enhanced during the treatment periods, whereas spontaneous proliferation was inhibited. Moreover, correlations between immune parameters and subsequent clinical responses were present in the early phase of the study. Cytotoxicity levels generated in vivo as well as the percentage of CD 56+ lymphocytes were higher in patients who responded to treatment than in non-responders. In contrast, responders had lower levels of CD 25+ cells. These findings indicate that it might be possible to select patients who are likely to benefit from prolonged immunotherapy.
Affiliation:
CRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.
Citation:
Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. 1993, 67 (1):163-71 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jan-1993
URI:
http://hdl.handle.net/10541/99949
PubMed ID:
7678979
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorVon Rohr, Aen
dc.contributor.authorGhosh, Anna Ken
dc.contributor.authorThatcher, Nicken
dc.contributor.authorStern, Peter Len
dc.date.accessioned2010-05-27T15:24:03Z-
dc.date.available2010-05-27T15:24:03Z-
dc.date.issued1993-01-
dc.identifier.citationImmunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. 1993, 67 (1):163-71 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid7678979-
dc.identifier.urihttp://hdl.handle.net/10541/99949-
dc.description.abstractTreatment with combined IL-2 and alpha-IFN has resulted in synergistic antitumour efficacy in animal studies. The mechanisms responsible for this synergy remain unclear. In this study, several immune parameters which might be involved in mediating antitumour activity have been monitored serially in 15 patients with advanced malignant melanoma or renal cell cancer during treatment with concurrent IL-2 and alpha-IFN. Both drugs were given subcutaneously in low to moderate (outpatient) dosages but for a prolonged duration. This treatment resulted in remarkable immunomodulation. In vivo induction of cytotoxicity against K562 and Daudi target cells was consistently seen, and percentages of peripheral blood cells expressing CD 25 (IL-2 receptor) and CD 56 (Leu-19) increased. In vitro proliferation of lymphocytes in response to IL-2 was enhanced during the treatment periods, whereas spontaneous proliferation was inhibited. Moreover, correlations between immune parameters and subsequent clinical responses were present in the early phase of the study. Cytotoxicity levels generated in vivo as well as the percentage of CD 56+ lymphocytes were higher in patients who responded to treatment than in non-responders. In contrast, responders had lower levels of CD 25+ cells. These findings indicate that it might be possible to select patients who are likely to benefit from prolonged immunotherapy.en
dc.language.isoenen
dc.subjectKidney Canceren
dc.subjectCultured Tumour Cellsen
dc.subjectBiological Tumour Markersen
dc.subject.meshAdjuvants, Immunologic-
dc.subject.meshAntigens, CD-
dc.subject.meshAntigens, CD56-
dc.subject.meshAntigens, Differentiation, T-Lymphocyte-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Renal Cell-
dc.subject.meshDrug Synergism-
dc.subject.meshHumans-
dc.subject.meshInterferon Alfa-2a-
dc.subject.meshInterleukin-2-
dc.subject.meshKidney Neoplasms-
dc.subject.meshLymphocyte Activation-
dc.subject.meshLymphocytes-
dc.subject.meshMelanoma-
dc.subject.meshPhytohemagglutinins-
dc.subject.meshReceptors, Interleukin-2-
dc.subject.meshStimulation, Chemical-
dc.subject.meshTumor Cells, Cultured-
dc.subject.meshTumor Markers, Biological-
dc.titleImmunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.